Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Researchers from the Oxford University Clinical Research Unit in Vietnam have shown that using a rapid (5-minute) test can reduce antibiotic misuse for respiratory infections. Cutting the number of unnecessary antibiotic prescriptions is a key way to prevent the spread of antibiotic-resistant infections.

CTMGH logo for News

Researchers from the Oxford University Clinical Research Unit in Vietnam have shown that using a rapid (5-minute) test can reduce antibiotic misuse for respiratory infections. Cutting the number of unnecessary antibiotic prescriptions is a key way to prevent the spread of antibiotic-resistant infections.

The rapid tests detect C-reactive protein (CRP), a marker of infections caused by bacteria, in patients’ blood. A low level of CRP is suggestive of viral infection and therefore antibiotic treatment is not required.

The study team made the tests available at 10 primary healthcare centres in and around Hanoi, Vietnam, and recorded antibiotic use for 2000 patients who randomly were or were not tested for CRP. The results showed a significant reduction of antibiotic use in adults and children while clinical recovery was the same. This trial was the first to investigate this in a resource-constrained setting and showed similar results to trials in Europe. This was also the first trial to assess CRP tests for children.

Read more »

Similar stories

RECOVERY trial closes recruitment to convalescent plasma treatment for patients hospitalised with COVID-19

@Oxford Research

Convalescent plasma has been widely used as a treatment for COVID-19 but to date there has been no convincing evidence of the effect of convalescent plasma on clinical outcomes in patients admitted to hospital with COVID-19. Recruitment to the convalescent plasma arm of the RECOVERY trial has now closed. The preliminary analysis based on 1873 reported deaths among 10,406 randomised patients shows no significant difference in the primary endpoint of 28-day mortality. Recruitment to all other treatment arms – tocilizumab, aspirin, colchicine, and Regeneron’s antibody cocktail – continues as planned.

Check-list recommended to improve reporting of microscopy methods and results in malaria studies

@Oxford MORU Publication Research

A study to explore the variations of how microscopy methods are reported in published malaria studies has recommended standardised procedures should be implemented for methodological consistency and comparability of clinical trial outcomes.

Pearl Gan, OUCRU Photographer in Residence, selected for the Lancet Highlights 2020

OUCRU

Congratulations to Pearl Gan, OUCRU Photographer in Residence, for her winning image selected for the Lancet Highlights 2020: Framing Health Stories. Despite the difficulties of this pandemic year, The Lancet received fascinating and varied entries for our Highlights 2020 photography competition. 15 striking photographs were selected. Each picture captures a unique moment, highlighting a health story.

Receiving and responding to community feedback during health system crises in Kenya

KWTRP Publication Research

The responsiveness of a health system is one of its goals, alongside fairness in financing and outcomes. Listening and responding to the public can make a health system stronger and fairer. However, responsiveness is likely to be undermined, especially for vulnerable and marginal populations, in periods of crises such as disease outbreaks. In the current COVID-19 crisis, there has been more focus on health system control interventions, with minimal consideration of community views. KWTRP colleagues in Kenya consider community engagement and citizens feedback channels, concerns raised by the public and how they were handled, and highlight lessons learned.

RECOVERY trial finds no benefit from azithromycin in patients hospitalised with COVID-19

@Oxford Research

Established in March 2020, the RECOVERY trial tests a range of potential treatments for COVID-19, including azithromycin, a widely used antibiotic that also reduces inflammation. The azithromycin arm of the trial was established to determine whether or not the drug has a meaningful benefit among patients hospitalised with COVID-19. A preliminary analysis shows no significant difference in the primary endpoint of 28-day mortality; there was also no evidence of beneficial effects on the risk of progression to mechanical ventilation or length of hospital stay.

New study on the risk of Plasmodium vivax parasitaemia after Plasmodium falciparum malaria

@Oxford MORU Publication Research

A new study quantifying the high risk of Plasmodium vivax parasitaemia after treatment of Plasmodium falciparum malaria aims to identify populations in which a policy of universal radical cure, combining artemisinin-based combination therapy with a hypnozoitocidal antimalarial drug, would be most beneficial.